J-code: Drugs administered other than oral method; chemotherapy drugs Drugs administered other than oral method; chemotherapy drugs
1,255 codes
Billing context
J-codes are permanent national codes for drugs and biologicals — most often clinician-administered (buy-and-bill) products paid under Medicare Part B — plus certain immunosuppressive, inhalation (via DME), and oral anticancer/antiemetic drugs. Units are reported in multiples of the dosage in the code descriptor.
| Code | Long descriptor | Payment limit (Q4 2026) | Added | Status |
|---|---|---|---|---|
| J0480 | Injection, basiliximab, 20 mg | $4,917.630per 20 MG | Jan 1, 2006 | Active |
| J0485 | Injection, belatacept, 1 mg | $3.883per 1 MG | Jan 1, 2013 | Active |
| J0490 | Injection, belimumab, 10 mg | $58.333per 10 MG | Jan 1, 2012 | Active |
| J0491 | Injection, anifrolumab-fnia, 1 mg | $18.461per 1 MG | Apr 1, 2022 | Active |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | $12.061per 20 MG | Jan 1, 1986 | Active |
| J0515 | Injection, benztropine mesylate, per 1 mg | $12.262per 1 MG | Jan 1, 1982 | Active |
| J0517 | Injection, benralizumab, 1 mg | $165.080per 1 MG | Jan 1, 2019 | Active |
| J0520 | Injection, bethanechol chloride, myotonachol or urecholine, up to 5 mg | — | Jan 1, 1984 | Active |
| J0525 | Injection, cefotetan disodium, 10 mg | — | Oct 1, 2025 | Active |
| J0528 | Injection, fosfomycin disodium, 20 mg | $0.633per 20 MG | Jul 1, 2026 | Active |
| J0558 | Injection, penicillin g benzathine and penicillin g procaine, 100,000 units | $19.523per 100,000 UNITS | Jan 1, 2011 | Active |
| J0561 | Injection, penicillin g benzathine, 100,000 units | $25.612per 100,000 UNITS | Jan 1, 2011 | Active |
| J0565 | Injection, bezlotoxumab, 10 mg | — | Jan 1, 2018 | Active |
| J0567 | Injection, cerliponase alfa, 1 mg | — | Jan 1, 2019 | Active |
| J0570 | Buprenorphine implant, 74.2 mg | — | Jan 1, 2017 | Active |
| J0571 | Buprenorphine, oral, 1 mg | — | Jan 1, 2015 | Active |
| J0572 | Buprenorphine/naloxone, oral, less than or equal to 3 mg buprenorphine | — | Jan 1, 2015 | Active |
| J0573 | Buprenorphine/naloxone, oral, greater than 3 mg, but less than or equal to 6 mg buprenorphine | — | Jan 1, 2015 | Active |
| J0574 | Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine | — | Jan 1, 2015 | Active |
| J0575 | Buprenorphine/naloxone, oral, greater than 10 mg buprenorphine | — | Jan 1, 2015 | Active |
| J0576 | Injection, buprenorphine extended-release (brixadi), 1 mg | — | Jan 1, 2024 | Ended Mar 31, 2024 |
| J0577 | Injection, buprenorphine extended-release (brixadi), less than or equal to 7 days of therapy | $433.167per Less than or equal to 7 days of therapy | Apr 1, 2024 | Active |
| J0578 | Injection, buprenorphine extended release (brixadi), greater than 7 days and up to 28 days of therapy | $1,732.667per Greater than 7 days and up to 28 days of therapy | Apr 1, 2024 | Active |
| J0582 | Injection, bivalirudin (endo), not therapeutically equivalent to j0583, 1 mg | $0.168per 1 MG | Oct 1, 2025 | Active |
| J0583 | Injection, bivalirudin, 1 mg | $0.165per 1 MG | Jan 1, 2004 | Active |
| J0584 | Injection, burosumab-twza 1 mg | $516.850per 1 MG | Jan 1, 2019 | Active |
| J0585 | Injection, onabotulinumtoxina, 1 unit | $6.514per 1 UNIT | Jan 1, 1991 | Active |
| J0586 | Injection, abobotulinumtoxina, 5 units | $8.937per 5 Unit | Jan 1, 2010 | Active |
| J0587 | Injection, rimabotulinumtoxinb, 100 units | $13.301per 100 UNITS | Jan 1, 2002 | Active |
| J0588 | Injection, incobotulinumtoxin a, 1 unit | $5.262per 1 UNIT | Jan 1, 2012 | Active |
| J0589 | Injection, daxibotulinumtoxina-lanm, 1 unit | $3.252per 1 UNIT | Apr 1, 2024 | Active |
| J0591 | Injection, deoxycholic acid, 1 mg | — | Jul 1, 2020 | Active |
| J0592 | Injection, buprenorphine hydrochloride, 0.1 mg | $4.698per 0.1 MG | Jan 1, 2003 | Active |
| J0593 | Injection, lanadelumab-flyo, 1 mg (code may be used for medicare when drug administered under direct supervision of a physician, not for use when drug is self-administered) | $88.340per 1 mg | Oct 1, 2019 | Active |
| J0594 | injection, busulfan, 1 mg | $0.839per 1 MG | Jan 1, 2007 | Active |
| J0595 | Injection, butorphanol tartrate, 1 mg | $11.316per 1 MG | Jan 1, 2004 | Active |
| J0596 | Injection, c1 esterase inhibitor (recombinant), ruconest, 10 units | $37.810per 10 UNITS | Jan 1, 2016 | Active |
| J0597 | Injection, c-1 esterase inhibitor (human), berinert, 10 units | $79.329per 10 UNITS | Jan 1, 2011 | Active |
| J0598 | Injection, c-1 esterase inhibitor (human), cinryze, 10 units | $67.065per 10 UNITS | Jan 1, 2010 | Active |
| J0599 | Injection, c-1 esterase inhibitor (human), (haegarda), 10 units | — | Jan 1, 2019 | Active |
| J0600 | Injection, edetate calcium disodium, up to 1000 mg | $6,273.865per 1000 MG | Jan 1, 1982 | Active |
| J0601 | Sevelamer carbonate (renvela or therapeutically equivalent), oral, 20 mg (for esrd on dialysis) | — | Jan 1, 2025 | Active |
| J0602 | Sevelamer carbonate (renvela or therapeutically equivalent), oral, powder, 20 mg (for esrd on dialysis) | — | Jan 1, 2025 | Active |
| J0603 | Sevelamer hydrochloride (renagel or therapeutically equivalent), oral, 20 mg (for esrd on dialysis) | — | Jan 1, 2025 | Active |
| J0604 | Cinacalcet, oral, 1 mg, (for esrd on dialysis) | — | Jan 1, 2018 | Active |
| J0605 | Sucroferric oxyhydroxide, oral, 5 mg (for esrd on dialysis) | — | Jan 1, 2025 | Active |
| J0606 | Injection, etelcalcetide, 0.1 mg | — | Jan 1, 2018 | Active |
| J0607 | Lanthanum carbonate, oral, 5 mg (for esrd on dialysis) | — | Jan 1, 2025 | Active |
| J0608 | Lanthanum carbonate, oral, powder, 5 mg, not therapeutically equivalent to j0607 (for esrd on dialysis) | — | Jan 1, 2025 | Active |
| J0609 | Ferric citrate, oral, 3 mg ferric iron, (for esrd on dialysis) | — | Jan 1, 2025 | Active |
| J0610 | Injection, calcium gluconate (fresenius kabi), per 10 ml | — | Jan 1, 1982 | Ended Mar 31, 2023 |
| J0611 | Injection, calcium gluconate (wg critical care), per 10 ml | — | Jan 1, 2023 | Ended Mar 31, 2023 |
| J0612 | Injection, calcium gluconate, not otherwise specified, 10 mgNOC / NOS | $0.024per 10 MG | Apr 1, 2023 | Active |
| J0613 | Injection, calcium gluconate (wg critical care), not therapeutically equivalent to j0612, 10 mg | $0.041per 10 MG | Apr 1, 2023 | Active |
| J0614 | Injection, treosulfan, 50 mg | $32.330per 50 MG | Oct 1, 2025 | Active |
| J0615 | Calcium acetate, oral, 23 mg (for esrd on dialysis) | — | Jan 1, 2025 | Active |
| J0616 | Injection, metoprolol tartrate, 1 mg | $0.140per 1 MG | Jul 1, 2025 | Active |
| J0618 | Injection, calcium chloride, 2 mg | — | Jul 1, 2025 | Active |
| J0620 | Injection, calcium glycerophosphate and calcium lactate, per 10 ml | — | Jan 1, 1982 | Active |
| J0630 | Injection, calcitonin salmon, up to 400 units | — | Jan 1, 1982 | Active |
| J0636 | Injection, calcitriol, 0.1 mcg | — | Jan 1, 2003 | Active |
| J0637 | Injection, caspofungin acetate, 5 mg | $2.463per 5 MG | Jan 1, 2003 | Active |
| J0638 | Injection, canakinumab, 1 mg | $156.953per 1 MG | Jan 1, 2011 | Active |
| J0640 | Injection, leucovorin calcium, per 50 mg | — | Jan 1, 1982 | Ended Sep 30, 2026 |
| J0641 | Injection, levoleucovorin, not otherwise specified, 0.5 mgNOC / NOS | $0.053per 0.5 MG | Jan 1, 2009 | Active |
| J0642 | Injection, levoleucovorin (khapzory), 0.5 mg | $1.336per 0.5 MG | Oct 1, 2019 | Active |
| J0643 | Injection, leucovorin calcium, not otherwise specified, 1 mg | $0.054per 1 MG | Oct 1, 2026 | Active |
| J0644 | Injection, leucovorin calcium (avyxa), 1 mg | $2.625per 1 MG | Oct 1, 2026 | Active |
| J0650 | Injection, levothyroxine sodium, not otherwise specified, 10 mcgNOC / NOS | $6.581per 10 MCG | Apr 1, 2024 | Active |
| J0651 | Injection, levothyroxine sodium (fresenius kabi), not therapeutically equivalent to j0650, 10 mcg | $7.079per 10 MCG | Apr 1, 2024 | Active |
| J0652 | Injection, levothyroxine sodium (hikma), not therapeutically equivalent to j0650, 10 mcg | $6.315per 10 MCG | Apr 1, 2024 | Active |
| J0654 | Injection, liothyronine, 1 mcg | — | Jan 1, 2026 | Active |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mgNOC / NOS | $0.010per 0.5 MG | Jul 1, 2023 | Active |
| J0666 | Injection, bupivacaine liposome, 1 mg | $1.426per 1 MG | Jan 1, 2025 | Active |
| J0668 | Instillation, bupivacaine and meloxicam, 1 mg/0.03 mg | — | Oct 1, 2025 | Active |
| J0670 | Injection, mepivacaine hydrochloride, per 10 ml | $4.367per 10 ML | Jan 1, 1986 | Active |
| J0675 | Injection, carboprost tromethamine, 0.1 mg | — | Oct 1, 2025 | Active |
| J0681 | Injection, ceftobiprole medocaril sodium, 3 mg | $1.098per 3 MG | Oct 1, 2025 | Active |
| J0687 | Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg | $0.663per 500 MG | Jul 1, 2024 | Active |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | $0.829per 500 MG | Jan 1, 2024 | Active |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | $1.281per 500 MG | Jan 1, 2023 | Active |
| J0690 | Injection, cefazolin sodium, 500 mg | $0.781per 500 MG | Jan 1, 1982 | Active |
| J0691 | Injection, lefamulin, 1 mg | — | Jul 1, 2020 | Active |
| J0692 | Injection, cefepime hydrochloride, 500 mg | $1.292per 500 MG | Jan 1, 2002 | Active |
| J0693 | Injection, cefiderocol, 5 mg | — | Jan 1, 2021 | Ended Sep 30, 2021 |
| J0694 | Injection, cefoxitin sodium, 1 gm | $5.416per 1 GM | Jan 1, 1992 | Active |
| J0695 | Injection, ceftolozane 50 mg and tazobactam 25 mg | $10.015per 75mg (50mg cft/25mg taz) | Jan 1, 2016 | Active |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | $0.390per 250 MG | Jan 1, 1990 | Active |
| J0697 | Injection, sterile cefuroxime sodium, per 750 mg | $2.106per 750 MG | Jan 1, 1990 | Active |
| J0698 | Injection, cefotaxime sodium, per gm | — | Jan 1, 1991 | Active |
| J0699 | Injection, cefiderocol, 10 mg | $2.564per 10 mg | Oct 1, 2021 | Active |
| J0701 | Injection, cefepime hydrochloride (baxter), not therapeutically equivalent to maxipime, 500 mg | $6.096per 500 MG | Jan 1, 2023 | Active |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | $7.175per 3 MG & 3 MG | Jan 1, 1995 | Active |
| J0703 | Injection, cefepime hydrochloride (b braun), not therapeutically equivalent to maxipime, 500 mg | $4.748per 500 MG | Jan 1, 2023 | Active |
| J0706 | Injection, caffeine citrate, 5 mg | — | Jan 1, 2002 | Active |
| J0710 | Injection, cephapirin sodium, up to 1 gm | — | Jan 1, 1982 | Ended Dec 31, 2025 |
| J0712 | Injection, ceftaroline fosamil, 10 mg | $4.008per 10 MG | Jan 1, 2012 | Active |
| J0713 | Injection, ceftazidime, per 500 mg | $1.549per 500 MG | Jan 1, 1996 | Active |
| J0714 | Injection, ceftazidime and avibactam, 0.5 g/0.125 g | $109.454per .625 GM | Jan 1, 2016 | Active |
| J0715 | Injection, ceftizoxime sodium, per 500 mg | — | Jan 1, 1995 | Ended Dec 31, 2025 |